AU2002216864A1 - Conjugates of antibodies and anticancer drugs - Google Patents

Conjugates of antibodies and anticancer drugs

Info

Publication number
AU2002216864A1
AU2002216864A1 AU2002216864A AU1686402A AU2002216864A1 AU 2002216864 A1 AU2002216864 A1 AU 2002216864A1 AU 2002216864 A AU2002216864 A AU 2002216864A AU 1686402 A AU1686402 A AU 1686402A AU 2002216864 A1 AU2002216864 A1 AU 2002216864A1
Authority
AU
Australia
Prior art keywords
conjugates
antibodies
anticancer drugs
anticancer
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002216864A
Inventor
Veronique Guillemard
H. Uri Saragovi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Publication of AU2002216864A1 publication Critical patent/AU2002216864A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU2002216864A 2000-12-21 2001-12-21 Conjugates of antibodies and anticancer drugs Abandoned AU2002216864A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25698700P 2000-12-21 2000-12-21
US60/256,987 2000-12-21
PCT/CA2001/001854 WO2002049672A2 (en) 2000-12-21 2001-12-21 Conjugates of antibodies and anticancer drugs

Publications (1)

Publication Number Publication Date
AU2002216864A1 true AU2002216864A1 (en) 2002-07-01

Family

ID=22974423

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002216864A Abandoned AU2002216864A1 (en) 2000-12-21 2001-12-21 Conjugates of antibodies and anticancer drugs

Country Status (4)

Country Link
US (1) US20040115209A1 (en)
EP (1) EP1343531A2 (en)
AU (1) AU2002216864A1 (en)
WO (1) WO2002049672A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110034381A1 (en) * 2002-01-22 2011-02-10 David Kleinberg Methods for Therapeutic Treatment of Benign Prostatic Hypertrophy (BPH)
CA2542834C (en) 2003-10-21 2012-04-24 Igf Oncology, Llc Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents
US9011880B2 (en) 2003-10-21 2015-04-21 Igf Oncology, Llc Compounds and methods for treating cancer
KR20080030564A (en) * 2005-05-12 2008-04-04 태피스트리 파마슈티컬스 인코퍼레이티드 Molecular constructs suitable for targeted conjugates
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc Prostate specific membrane antigen antibodies and antigen binding fragments
FR2959994B1 (en) * 2010-05-12 2012-08-24 Lfb Biotechnologies NOVEL 12G4 MUTUS HUMANIZED ANTIBODIES AND THEIR FRAGMENTS DIRECTED AGAINST THE HUMAN TYPE II ANTI-MULLERIAN HORMONE RECEPTOR
AU2015204540B2 (en) 2014-01-12 2020-03-19 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
EP3630195A4 (en) 2017-05-21 2021-03-24 IGF Oncology, LLC An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5084560A (en) * 1986-06-30 1992-01-28 Oncogen Immunoconjugates and methods for their use in tumor therapy
ES2006109A6 (en) * 1987-03-11 1989-04-01 Erba Carlo Spa Idarubicin immunoglobulin conjugates
US5833983A (en) * 1987-06-29 1998-11-10 The United States Of America As Represented By The Secretary Of Dept. Of Health And Human Services Interleukin 2 receptor and applications thereof
FI102355B1 (en) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co A method for preparing anthracycline immunoconjugates having a linking spacer
CA2016584C (en) * 1989-05-17 1999-06-29 Robert S. Greenfield Anthracycline conjugates having a novel linker and methods for their production
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5208323A (en) * 1989-08-10 1993-05-04 Universite Laval Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
CA2048089A1 (en) * 1990-09-17 1992-03-18 Wolfgang A. Wrasidlo Chemical conjugation of morpholino anthracyclines to antibodies
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
DE4433890C2 (en) * 1994-09-22 1999-02-18 Deutsches Krebsforsch Conjugate of an active ingredient and a native protein that is not considered foreign to the body
GB9525180D0 (en) * 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
JP2003514903A (en) * 1999-11-24 2003-04-22 イムノージェン インコーポレーテッド Taxane-containing cytotoxic drugs and their therapeutic use

Also Published As

Publication number Publication date
US20040115209A1 (en) 2004-06-17
WO2002049672A3 (en) 2003-01-03
EP1343531A2 (en) 2003-09-17
WO2002049672A2 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
AU7912100A (en) Pharmaceutical composition comprising an antigen
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
AU2002366042A1 (en) Solid dispersions containing substituted cyclodextrin and insoluble drug and their preparations
AU2001269508A1 (en) Drugs or cosmetics
IL146842A0 (en) Polymer conjugates of hedgehog proteins and uses
AU2002305478A1 (en) Conjugates of reduced antibodies and biomolecules
AU2002225878A1 (en) Receptor antagonist-lipid conjugates and delivery vehicles containing same
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
AU2002361559A1 (en) Anticancer vaccine and diganostic methods and reagents
AU2001289635A1 (en) Polymeric conjugates of antitumor agents
AU2001275821A1 (en) Anti-cancer composition composed of anti-cancer and anti-malarial drugs
AUPQ342599A0 (en) Conjugates and uses thereof
AU2002216864A1 (en) Conjugates of antibodies and anticancer drugs
AU2002221099A1 (en) Combination drugs
AU2002214876A1 (en) Combination preparation of a biological response modifier and an anticancer agent and uses thereof
AU2002230781A1 (en) Pharmaceutical uses and synthesis of benzobicyclooctanes
AU2001274535A1 (en) Hydroxyformamidine derivatives and medicines containing the same
AU2002212327A1 (en) Pharmaceutical preparation comprised of milk-thistle and terpenes
AU2001282527A1 (en) Antiparkinsonism drugs
AU2002212863A1 (en) Stable pharmaceutical form of an anticancer drug
AU4940800A (en) Polyketides and their synthesis
AU5632500A (en) Cancer associated antigens and uses therefor
AU6167696A (en) Preparation of immunogens and other conjugates of drugs
AU2002358354A1 (en) Sugar-protein conjugates and their formation
AU1172101A (en) Phytoestrogenic pharmaceutical preparations